Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

392 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Erratum to: The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach.
Levin J, Maaß S, Schuberth M, Respondek G, Paul F, Mansmann U, Oertel WH, Lorenzl S, Krismer F, Seppi K, Poewe W, Wenning G, Berg D, Claßen J, Ebersbach G, Eggert K, Kassubek J, Lipp A, Löhle M, Mollenhauer B, Münchau A, Südmeyer M, Blankenstein C, Eberhardt C, Ertl-Wagner B, Heise H, Ricard I; PROMESA study group; Giese A, Bötzel K, Höglinger G. Levin J, et al. Among authors: classen j. J Neural Transm (Vienna). 2016 Nov;123(11):1357-1358. doi: 10.1007/s00702-016-1602-x. J Neural Transm (Vienna). 2016. PMID: 27562771 No abstract available.
α-Synuclein in Parkinson's disease: causal or bystander?
Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Krüger R, Müller T, Reichmann H, Rieß O, Storch A, Strobel S, van Eimeren T, Völker HU, Winkler J, Winklhofer KF, Wüllner U, Zunke F, Monoranu CM. Riederer P, et al. Among authors: classen j. J Neural Transm (Vienna). 2019 Jul;126(7):815-840. doi: 10.1007/s00702-019-02025-9. Epub 2019 Jun 25. J Neural Transm (Vienna). 2019. PMID: 31240402 Review.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
[Relevance of COMT inhibitors in the treatment of motor fluctuations].
Jost WH, Buhmann C, Classen J, Eggert K, Kohl Z, Outeiro T, Tönges L, Woitalla D, Reichmann H. Jost WH, et al. Among authors: classen j. Nervenarzt. 2022 Oct;93(10):1035-1045. doi: 10.1007/s00115-021-01237-3. Epub 2022 Jan 19. Nervenarzt. 2022. PMID: 35044481 Review. German.
Frequency and treatment of depressive symptoms in a Parkinson's disease registry.
Althaus A, Becker OA, Spottke A, Dengler R, Schneider F, Kloss M, Eggert K, Oertel WH, Dillmann U, Herting B, Classen J, Dodel R. Althaus A, et al. Among authors: classen j. Parkinsonism Relat Disord. 2008 Dec;14(8):626-32. doi: 10.1016/j.parkreldis.2008.01.016. Epub 2008 Apr 11. Parkinsonism Relat Disord. 2008. PMID: 18406197
392 results